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Abstract
Background: Intervertebral disc (IVD) disorders are often accompanied by painful inflammatory and
immunopathological processes. Nucleus pulposus (NP) cells play a pivotal role in maintenance of IVD by
organizing the expression of anabolic, catabolic, anti-catabolic and inflammatory cytokines. Human NP cells
have been targeted by gene therapeutic approaches using lentiviral or adenoviral systems that could be
critical due to genome incorporation or immunological side effects. Adeno-associated viruses (AAVs), which
do not express any viral gene and are not linked with any known disease in humans, are attractive gene
delivery vectors. However, their lack of specific tissue tropism and preexisting immune response are main
problems for therapeutic applications. Heretofore, AAVs have not been studied in human IVD research.
Therefore, we attempted to identify NP cell specific AAV serotype by targeting human NP cells with different
self-complementary AAV (scAAV) serotypes.
Identification and characterization of the proper serotype is crucial to establish less immunogenic and safer
gene therapeutic approaches of IVD disorders.
Methods: Preoperative magnetic resonance imaging (MRI) was used for grading of IVD degeneration. NP cells were
isolated, cultured with low-glucose and transduced with green fluorescent protein (GFP) packing scAAV serotypes
(scAAV1-8) in a dose-dependent manner. scAAV titers were determined by quantitative polymerase chain reaction
(qPCR). Transduction efficiencies were determined by fluorescence microscopy and fluorescence-activated cell sorting
within 48 days of post-transduction. The 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay was
used to determine NP cell viability. Three-dimensional (3D) cell culture and enzyme-linked immunosorbant assay
(ELISA) were performed to examine the expression levels of inflammatory, catabolic and matrix proteins in NP cells.
Results: scAAV6, scAAV2 and scAAV3 showed high and prolonged transgene GFP expressions with transdution
efficiencies of 98.6 %, 91.5 % and 89.6 % respectively (p ≤ 0.002). Unlike scAAV6, the serotypes scAAV2 and scAAV3
declined the viability of NP cells by about 25 % and 10 % respectively (p ≤ 0.001). Moreover, scAAV6 did not affect the
expression of the inflammatory, catabolic and matrix proteins.
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Conclusions: As original primary research evaluating AAVs in degenerative human IVDs, this study identified scAAV6 as
a proper serotype for high, stable and non-immunogenic target gene expression in human NP cells. The data could be
very important to design efficient and safer gene therapeutic approaches of IVD disorders.
Keywords: Intervertebral disc disorders, Inflammatory and catabolic cytokines, Nucleus pulposus cells, Nucleus
pulposus cell specific adeno-associated virus, Targeted gene therapy, Maintenance of intervertebral disc matrix
Background
Painful progressive degeneration of IVD, referred to as
degenerative disc disorders, has a dramatic influence on
the quality of life and causes exceedingly high health care
and other socioeconomic expenses [1–4]. Structural failure
with accelerated grade of degeneration is usually accom-
panied by painful inflammatory and patho-immunological
processes [5–7]. They are associated with upregulation of
pain-mediating inflammatory cytokines, pathological in-
growth of nerves into the inner layers of IVD and progres-
sive spinal instabilities [8–14]. Although current surgical
treatment procedures provide relief to the pain and disabil-
ity, they are not able to restore the biological functions of
the IVD. Nevertheless, in vitro and in vivo researches of
IVD degeneration have identified several therapeutic target
genes with significant impact on IVD matrix anabolism
and catabolism [15–18]. This provides the opportunity to
develop novel gene therapeutic approaches. Gene thera-
peutic approaches of degenerative discs have been tried in
vitro and in small animal models through transgenic
expression of anabolic factors or inhibition of catabolic or
inflammatory cytokines [19–23].
They are usually performed using lentiviral or adeno-
viral gene delivery systems, which could be critical for
future clinical applications due to random gene incorp-
oration and immune reactions [24–33]. An alternative
gene delivery system could be the AAV system, which is
stable, less immunogenic, non-pathogenic and possibly
safer. AAV does not express any viral gene and, as yet, it
has not been linked with any known disease in humans
[34, 35]. It can have high transduction efficiency in
dividing and non-dividing cells and permit prolonged
transgene expression of therapeutic genes [34, 35]. In
naturally occurring AAV the second strand synthesis is
considered to be one of several blocks to efficient infec-
tion. However, in the modified form of AAV, known as
self-complementary AAV (scAAV), the right inverted
terminal repeat (ITR) contains a deletion of D-sequence
(the packaging signal) and a terminal resolution site
mutation (Δtrs), which prevent Rep mediated nicking
and force packaging of dimer or self-complementary
genomes [36]. This makes scAAV attractive for gene
therapeutic approaches.
There are different AAV serotypes described in the lit-
erature that could infect human cells from diverse tissue
types with differences in cellular tropism [37]. The use of
AAV for targeted gene therapy in human intervertebral
disc research is a new approach that has not yet been
studied. So far, identification of specific AAV serotypes
having human IVD tissue tropism is not attempted.
Here we tried to efficiently target degenerative human
NP cells using different scAAV serotypes (scAAV1-8).
Preoperative MRI was used for grading of lumbar disc
degeneration [38, 39]. Degenerative NP tissues were iso-
lated from patient IVDs of degeneration grade III-V,
which were operated due to lumbar disc herniation. NP
cells were then immediately isolated from the tissue,
cultured with low-glucose medium and transduced with
scAAV serotypes in a dose-dependent manner. scAAV
titers were determined by qPCR. Transduction efficien-
cies of of the serotypes were determined by the intensity
of transgene GFP expression using fluorescence micros-
copy and fluorescence-activated cell sorting (FACS)
within 48 days. MTT Assay was used to determine the
impact of scAAVs on NP cell viability. Three-
dimensional cell culture and ELISA were performed to
examine the influence of scAAVs on the expression
levels of inflammatory, catabolic and matrix proteins in
NP cells.
This is the first study to evaluate the serotypes of AAVs
in degenerative human IVDs and its findings might con-
tribute to design efficient and possibly safer gene thera-
peutic approaches of intervertebral disc disorders.
Methods
Ethics statement and NP tissue recruitment
Experimental studies with human IVD specimens were
approved by the local research ethics committee (Inns-
bruck Medical University: project AN2014-0027 333/
4.24). NP tissues were recruited from patients during
lumbar disc surgery with informed consents of the pa-
tients. Patients provided their written informed consent
to participate in this study. Disc degeneration grade
(DDG) was determined by preoperative MRI [38, 39].
NP tissues were recruited from NP compartment during
surgical procedure and taken to the laboratory in
sterile phosphate buffered saline solution (PBS)
(Sigma-Aldrich) for immediate cell isolation. Table 1
exhibits 12 lumbar discs involved in this study.
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NP cell isolation and monolayer cell culture
NP tissues were washed in PBS and separated from anulus
fibrosus (AF) on the basis of their macroscopic morph-
ology (identification of the innermost lamellar rings of the
AF). NP tissues were finely minced into small fragments
of approximately 2 mm3 and digested with 0.02 % w/v
pronase (Sigma-Aldrich) (37 °C, 5 % CO2, 1 h) in 20 ml
DMEM (Dulbecco's Modified Eagle's Medium), contain-
ing 1 % penicillin/streptomycin, 1 % glucose and 10 %
FCS (fetal calf serum) (Sigma-Aldrich). After filtration
through sterile 75 gm nylon mesh filters (Sigma-Aldrich)
and centrifugation of the supernatants (1000 x g, 2 min),
pellets were resuspended in 20 ml DMEM and digested
with 0.02 % w/v collagenase II (Sigma-Aldrich) and 100U
hyaluronidase (Sigma-Aldrich) (37 °C, 5 % CO2, 3 h).
Following filteration and centrifugation of supernatants,
pellets were resuspended in 10 ml DMEM and cultured in
25 cm2 tissue culture flask (Sigma-Aldrich) (37 °C, 5 %
CO2, 2 weeks) by changing the medium every two days.
Depending on the amount of cells that could be isolated
from the tissues, NP cells could reach 100 % con-
fluentbetween two and three weeks. Cells were cryo-
preserved at −196 °C in DMEM containing 30 % FCS and
15 % dimethyl sulfoxide (DMSO) (Sigma-Aldrich).
Helper virus free production of scAAV serotypes
The AAV helper virus free system provides a safer and
more convenient gene delivery system. Most of the
adenovirus gene products (E2A, E4, and VA RNA genes)
required for the production of infective recombinant
AAV (rAAV) particles are cloned on the helper plasmid
of the respective serotype (pDP1rs, pDP2rs, pDP3rs,
pDP4rs, pDP5rs, pDP6rs, and pDP8rs) (PlasmidFactory,
Bielefeld, Germany). For vector production of scAAV
serotypes, HEK293 cells were cultured in DMEM and
passaged 2 times prior to transfection. 5 × 106 cells were
grown in 15 cm culture dish of 20 ml culture medium to
a confluence of 70 - 80 %. 30 μg of the scAAV shuttle
plasmid [40], encoding the expression cassettes of GFP
under the control of human CMV promoter, and 96 μg
helper plasmids of the respective serotype were used for
co-transfection. 30 μg of the scAAV shuttle plasmid and
96 μg of the respective helper plasmid were added in
2.5 ml of 300 mM calcium phosphate (Sigma-Aldrich),
gently mixed with 2.5 ml of 2 x HBS (Hepes Buffered
Saline) (Sigma-Aldrich) and directly pipetted to the cul-
ture dish. Following incubation (37 °C, 5 % CO2, 6 h)
the transfection medium was changed with prewarmed
DMEM containing 2 % FCS. Transfected cells and cul-
ture medium were harvested 72 h after transfection and
centrifuged (2000 x g, 5 min). Pellet was resuspended in
2.5 ml of serum-free DMEM, treated with benzonase
(250 U/ml, 37 °C, 1 h) (Merck Millipore) and subjected
to four rounds of freeze/thaw cycles by alternating the
tube between the dry ice-ethanol bath and the 37 °C
water bath. AAV supernatant was then collected by cen-
trifugation (8000 x g, 30 min) and stored at −80 °C for
subsequent purification.
Purification and quantification of scAAV serotype vectors
Purification of scAAV serotype vectors was performed as
previously described [41]. Briefly scAAV vectors were
purified from benzonase treated and cleared freeze/
thaw-supernatants by iodixanol (Sigma-Aldrich) gradient
centrifugation. Iodixanol was then removed by running
the iodixanol fractions through PD10 gel filtration col-
umns (GE Healthcare). The eluate was collected in 10
fractions of 1 ml and fractions 4 to 6 were pooled and
used for quantification.
Quantitative PCR was applied for quantification of
scAAV vector titers using LightCycler 480 (Roche
Applied Science) and the TaqMan Gene Expression
Master Mix (Life Technologies). PCR reactions were
performed in 20 μl of final volume using 1× master
mix, supplemented with 100 nM sense, 100 nM anti-
sense primers of GFP and 2 μl of the standard tem-
plate DNA. The primers GFP-sense:ACGGCGACGTA
AACGGCCAC and GPF-antisense:GCGAAGCACTG
CACGCCGTA were used. Standard sample and negative
control were run in three replicates of a 96 well-plate. Lin-
earized scAAV vector (shuttle plasmid cleaved with KasI)
and genomic DNA of scAAV vector (scAAVstd) were used
as standard as previously described [42]. The PCR pro-
gramm had an initial denaturation step at 95 °C for
10 min, 40 cycles of denaturation at 95 °C for 15 s, an ex-
tension at 60 °C for 1 min and a melt curve stage (65 °C
to 95 °C, increment 0.5 °C). Data analysis was performed
Table 1 Lumbar NP tissue samples obtained from 12 patients
undergone surgery due to spinal disc herniation. Table shows
details of the NP tissue samples with disc level and disc
degeneration grade (DDG)













Mern and Thomé BMC Musculoskeletal Disorders  (2015) 16:341 Page 3 of 12
using the Applied Biosystems StepOne software v2.1 (Life
Technologies).
Transduction of human NP cells with scAAV serotype
vectors
NP cells from 12 lumbar discs of degeneration grade III-
V (Table 1) were seeded in 24-well plates at a density of
1 × 105 cells per well (about 50 % confluent) in a volume
of 500 μl culture medium containing 1 % FBS. The next
day NP cells of each lumbar disc were initially trans-
duced with scAAV1-8 at different doses of vector gen-
ome copy per seeded cell (5 vg/c, 50 vg/c, 500 vg/c and
5000 vg/c). After preliminary screening additional trans-
ductions were performed with selected serotypes and
effective dose to quantify the transduction efficiencies,
evaluate potential cell toxicities and determine pro-
longed transgene expressions.
Evaluation of transduction efficiencies using fluorescence
microscopy and FACS
For preliminary screening of scAAV serotypes having
human NP tissue tropism, transduced NP cells were
visualized using an AxioVert. A microscope (Carl Zeiss).
Fluorescence micrographs were acquired every 2 days
for the first 24 days and weekly up to 48 days of post-
transduction. Selected scAAV serotypes and viral dose,
which efficiently transduced NP cells, were used for fur-
ther quantification of transduction efficiencies by FACS.
For FACS analysis NP cells were seeded as described
above and transduced with selected scAAV serotypes
and viral dose. Transduced cells were harvested on day
8, 16, 24, 32 and 48, and 1 × 105 cells per sample were
counted. The proportion of GFP-positive cells was deter-
mined using MoFlo cell sorter (Beckman Coulter)
according to the manufacturer’s protocol. Briefly, a
MoFlo cell sorter with a 100-mm flow cell tip and a flow
rate of 12000 events per second, with an extention wave-
length of 488 nm and a laser power of 110 W was used.
Cell viability assay
To analyse the cytotoxic effects of scAAV serotypes,
which are able to effectively transduce human NP
cells, the number of viable NP cells were quantified
using 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazo-
lium bromide (MTT Assay Kit, Molecular Probes).
Transduced and non-transduced (negative control) NP
cells were harvested after 8, 16, 24, 32 and 48 days of
post-transduction. NP cells were trypsinated, centrifugated
and pellets were washed twice with 1 x PBS and resus-
pended in 250 μl culture medium. Duplicates of 100 μl
suspended cells were plated into flat-bottomed 96-well
plate. Duplicate control wells of medium alone were
added to provide the blanks for absorbance readings. After
incubation for recovering (37 °C, 5 % CO2, 24 h), 10 μl
MTT reagent was added to each well and incubated again
for 3 h. Then 100 μl of the SDS-HCl (Sodium dodecyl sul-
fate - hydrochloric acid) solution was added to each well
for further incubation of 4 h. The absorbance was mea-
sured at 570 nm in a microtiter plate reader Infinite 200
(TECAN) and the average value of the blank duplicate
readings was subtracted from the average values of the
sample duplicate readings. Number of viable NP cells was
calculated from the standard curve.
Three-dimensional NP cell culture
For three-dimensional culture (3D) of NP cells the collagen
type I scaffold of 24-well plate format was used (Viscofan
Bioengineering). 250 μl PBS (pH 7.3 without Ca2+/Mg2+)
was added to each well for attaching of the scaffold to the
bottom of the well. The scaffold was taken out of the blis-
ter with sterilized forceps, placed onto the PBS without
submerging and incubated at room temperature for
20 min. After removing of the remaining PBS, the plate
was left in the operating laminar flow hood overnight. The
scaffold was equilibrated with 250 ml pre-warmed culture
medium (37 °C, 5 % CO2, 10 min) and monolayer scAAV
transduced NP cells were transferred to collagen I scaffold
on day 8 of posttransduction. NP cells were cultured in
500 μl culture medium (37 °C, 5 % CO2) by changing the
culture medium every two days. As required, NP cells were
harvested by digestion of the scaffold with 0.02 % w/v col-
lagenase II in 250 μl medium (37 °C, 5 % CO2, 1 h). Cell
suspension was filtered through sterile 75 gm nylon mesh
filter and supernatant was centrifuged (1000 x g, 2 min).
Then pellet was washed twice in 1 ml PBS (1000 x g,
2 min) and processed for assays of inflammatory, catabolic
and matrix proteins expressions.
Enzyme-linked immunosorbant assay of inflammatory,
catabolic and matrix proteins
To examine the impact of scAAV vectors on the expres-
sion levels of inflammatory, catabolic and matrix pro-
teins in NP cells, ELISA was performed on 100 μg of
total protein extracts from each sample for each inde-
pendent experiment. As described above, NP cells were
seeded and transduced with the favoured scAAV sero-
type at its effective dose. On day 8 of post-transduction
NP cells were harvested and cell pellet was washed with
1 x PBS, resuspended in 500 μl culture medium and
three-dimensional cultured for 30 days. Cells were har-
vested by digestion of the scaffold as described above
and for protein isolation pellet was washed twice in cold
1 x PBS (2500 x g, 5 min) and resuspended with 100 μl
cold radio-immunoprecipitation assay (RIPA) buffer
(Sigma-Aldrich) containing protease and phosphatase
inhibitor cocktails (Sigma-Aldrich). After sonication at
50 % pulse for 30 s, the mixture was shacked gently on
ice (15 min), centrifuged (14000 x g, 4 °C and 15 min)
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and supernatant was transferred to new tube for protein
quantification. Protein concentration in sample was
determined using BCA Protein Assay Kit (Thermo
Scientific) according to the instruction manual. For meas-
uring the concentration of inflammatory, catabolic and
matrix proteins in NP cells ELISA kits were used (R&D
Systems, Uscn Life Science Inc). Assays were performed
according to the instruction manuals. The analysed target
proteins include: the inflammatory cytokines IL-1β (inter-
leukin-1β) and TNF-α (tumornekrosefaktor-α); the cata-
bolic factors ADAMTS-4, ADAMTS-5 (a disintegrin and
metalloproteinase with thrombospondin motifs) as well as
matrix proteins aggrecan and collagen type II.
Statistical data analysis
To estimate the reliability of the MRI evaluations of
IVD degeneration, Landis and Koch based interpreta-
tions with κ statistics and agreement percentage
among two observers (interobserver reliability) were
used [38, 39]. The software IBM SPSS Statistics 20,
Armonk New York USA was used for statistical ana-
lysis. 1-way ANOVA and pairwise comparisons were
used to compare scAAV treated and non-treated cells.
Significance was set at P < 0.05.
Results
Reliability of MRI grading
The interobserver reliability agreement between two ob-
servers, for the MRI rating of lumbar disc degeneration
grade, was perfect with 100 % frequency of agreement
and κ = 1.00.
Production of adenovirus free high-titer scAAV serotype
vectors
As described in materials and methods, scAAV serotype
vectors were produced, purified and quantified using
qPCR. High titers of scAAV vectors were verified for all
serotypes. Final titers between 3 × 1011 and 1.8 × 1012
vector genome copies were determined from 3 × 107
HEK293 cells.
Transduction efficiency of scAAV serotypes in NP cells
For the early screening of scAAV serotypes that may
have NP tissue tropism, NP cells from 12 lumbar discs
of degeneration grade III-V (Table 1) were transduced
with GFP packing scAAV serotypes at different viral
doses and fluorescence micrographs were acquired up to
48 days as described in materials and methods. The ini-
tial screening showed that the serotypes scAAV2,
scAAV3 and scAAV6 at the dose of 5000 vg/c could
transduce NP cells with highest efficiencies, as shown by
fluorescence micrographs from day 8 of post-
transduction (Fig. 1). The serotypes scAAV1, scAAV4,
scAAV5 and scAAV8 did not show any GFP expression
at all examined time and viral doses.
Based on the initial screening the serotypes scAAV2,
scAAV3 and scAAV6 and the viral dose 5000 vg/c were
selected for quantitative analysis of their transduction
efficiencies by FACS. As described above, transduced NP
cells were harvested on day 8, 16, 24, 32 and 48 of post-
transduction and 1 × 105 cells per sample were counted
to determine the proportion of GFP-positive cells. On
day 8 of post-transduction an average of 98.6 % GFP
positive cells were detected for scAAV6 with minimum
and maximum transduction values between 92.8 % and
99.9 % (Table 2 and Fig. 2). Lower transduction efficien-
cies of 91.6 % and 89.6 % were detected for scAAV2 and
scAAV3 with minimum and maximum transduction
values of (87.2 % & 95.4 %) and (85.0 % & 92.9 %) re-
spectively (p ≤ 0.002) (Table 2 and Fig. 2). Analysis of
samples on day 16 exhibited lower transduction efficien-
cies of 68.5 %, 60.3 % and 58.6 % for scAAV6, scAAV2
and scAAV3 with minimum and maximum transduction
values of (66.1 % & 71.5 %), (55.8 % & 65.9 %) and
(54.8 % & 60 %) respectively (p ≤ 0.005). On day 24, 32
and 48 decreasing transduction efficiencies of (61.5 %,
45.7 % & 38 %) for scAAV6, (53.6 %, 38.2 % & 31.2 %)
for scAAV2 and (52.3 %, 37.3 % & 29.4 %) for scAAV3
were detected (p ≤ 0.003). On all days of GFP detection
scAAV6 continuously displayed the highest transduction
efficiencies, whereas the transduction efficiencies scAAV2
and scAAV3 were comparable. The serotypes scAAV6,
scAAV2 and scAAV3 at transduction dose of 5000 vg/c
demonstrated long-term transgene expressions in NP
cells. Degeneration grades of IVDs did not show any influ-
ence on the transduction efficiencies of the analysed
serotypes.
Effect of scAAV2, scAAV3 and scAAV6 on the viability of
NP cells
To examine the potential impact of scAAV2, scAAV3
and scAAV6 on NP cell viability 1 × 105 NP cells were
transduced with scAAV2, scAAV3 and scAAV6 at a viral
dose of 5000 vg/c. MTT assays were done on day 8, 16,
24, 32 and 48 of post-transduction to quantify the num-
ber of viable NP cells. All through the days of MTT as-
says, similar viabilities of scAAV6 treated and untreated
cells (negative control) were recorded with mean num-
ber of viable cells (145643 ± 1411 and 149148 ± 1009) for
day 8 and (586593 ± 4967 and 589681 ± 3362) for day 48
respectively (p < 0.081) (Table 3 and Fig. 3). No morpho-
logical changes were observed between scAAV6 treated
and untreated NP cells, as shown as an example in Fig. 4.
The viability of scAAV2 treated cells was reduced by
about 25 % with mean number of viable cells (113127 ±
1668) and (463623 ± 3952) for day 8 and 48 respectively
(p < 0.001). Although the viability of scAAV3 treated
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cells was better than that of the scAAV2 treated cells,
their viability, related to that of the scAAV6 treated cells,
was reduced by more than 10 % with mean number of
viable cells (123754 ± 1406) and (529090 ± 4556) for day
8 and 48 respectively (p < 0.001) (Table 3 and Fig. 3).
Degeneration grades of IVDs did not show any influence
on the proliferation of NP cells.
Levels of inflammatory, catabolic and matrix proteins in
scAAV6 treated NP cells
The serotype scAAV6, showing the highest transduction
efficiency and no impact on viability of NP cells, can be
selected as the hot favourite serotype, if it does not pro-
mote the expression of unfavourable inflammatory and
catabolic proteins in NP cells. For protein expression
Fig. 1 Fluorescence micrographs of the initial scAAV serotype screening on day 8 of post-transduction. For the primary screening of the serotypes
in NP cells, 1 x 105 NP cells were seeded and transduced with GFP packing scAAV serotypes at different viral genome copies per seeded
cell (vg/c) and fluorescence micrographs were acquired up to 48 days. On day 8 of post-transduction scAAV2, scAAV3 and scAAV6 displayed the highest
transduction efficiencies at a dose of 5000 vg/c. Original magnification: x 40
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analysis monolayer transduced NP cells (scAAV6, 5000
vg/c) were transferred to collagen I scaffold on day 8 of
posttransduction and 3D cultured for four weeks. The
expression levels of inflammatory cytokines (IL-1β &
TNF-α), catabolic factors (ADAMTS-4 & ADAMTS-
5) and matrix proteins (aggrecan & collagen II) were
determined by using ELISA-assays applied on 100 μg
of total protein extracts of each sample. In all sam-
ples scAAV6 had shown no impact on the endoge-
neous expression levels of the inflammatory cytokines,
catabolic factors and matrix proteins. Figure 5 and
Table 4 exhibit the levels of protein expressions in
NP cells of disc degeneration grade III. Comparable
protein expression levels [pg/ml] of the inflammatory
cytokines were determined in untreated and scAAV6
treated samples with mean expression levels for IL-1β
(110 ± 2.247 and 109 ± 1.702) and TNF-α (93 ± 1.648
and 91 ± 2.314) respectively (p ≤ 0.097). Similarly, the
expression levels of the catabolic factors in untreated and
scAAV6 treated samples were equivalent with mean
expression levels [pg/ml] for ADAMTS-4 (1807 ± 79.49
and 1756 ± 105.6) and ADAMTS-5 (4156 ± 177.9 and
4042 ± 203.5) respectively (p ≤ 0.103). Moreover, the ex-
pression levels [pg/ml] of the matrix proteins in untreated
and treated samples were similar with mean expression
values for aggrecan (29100 ± 111 and 28804 ± 1279) and
collagen II (10311 ± 542.7 and 10171 ± 548.9) respectively
(p ≤ 0.082). Furthermore, the expression levels of the
Table 2 GFP based quantification of transduction efficiencies by FACS in NP cells transduced with scAAV serotypes
FACS day Serotype Min. value % Max. value % Range % Mean value % SD %
day 8 scAAV2 87.2 95.4 8.2 91.5 1.943
scAAV3 85.0 92.9 7.8 89.6 1.866
scAAV6 92.8 99.9 7.1 98.6 1.493
day 16 scAAV2 55.8 65.9 10.1 60.4 1.876
scAAV3 54.8 62.0 7.1 58.5 1.853
scAAV6 66.1 71.5 5.3 68.5 1.474
day 24 scAAV2 50.3 56.9 6.5 53.6 1.677
scAAV3 48.0 54.8 6.8 52.3 1.623
scAAV6 57.3 64.3 7.0 61.5 1.755
day 32 scAAV2 35.9 40.6 4.6 38.2 1.137
scAAV3 34.9 39.9 5.0 37.3 1.256
scAAV6 41.8 49.1 7.2 45.7 1.669
day 48 scAAV2 29.0 33.3 4.3 31.2 1.242
scAAV3 26.2 31.5 5.3 29.3 1.461
scAAV6 35.8 40.7 4.8 38.0 1.196
1 x 105 NP cells were seeded and transduced with scAAV2, scAAV3 and scAAV6 at viral dose of 5000 vg/c. FACS was done on day 8, 16, 24, 32 and 48
of post-transduction. Min and Max values represent the minimum and maximum transduction efficiencies measured throughout the NP samples. Range represents the
fluctuation between maximum and minimum values. Data represent the mean with standard deviation (SD) of three independent experiments, each performed in
triplicate (p < 0.05)
Fig. 2 FACS based transduction efficiencies of scAAV2, scAAV3 and scAAV6 in NP cells. 1 x 105 NP cells were seeded and after transduction at a
viral dose of 5000 vg/c, GFP positive cells were quantified by FACS on day 8, 16, 24, 32 and 48 of post-transduction. Data represent the mean with
standard deviation (SD) of three independent experiments, each performed in triplicate (p < 0.05). Error bars indicate SD values
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inflammatory, catabolic and matrix proteins were similar
in untreated and scAAV6 treated samples of disc degener-
ation grade IV and V (data not shown).
Discussion
The regenerative potential of gene therapeutic ap-
proaches in IVD cells has been shown in different publi-
cations. These include inhibition of catabolic and
inflammatory cytokines or activation anabolic factors
[13, 16, 43–46]. However, gene therapeutic approaches
in degenerative human disc cells have usually been per-
formed using lentiviral or adenoviral gene delivery sys-
tems that could be critical for future clinical applications
due to their immunological side effects [24–30]. The
genome-incorporating lentiviral gene delivery system can
randomly incorporate the exogenous therapeutic gene in
the host cell genome, which could inactivate crucial
housekeeping or tumor suppressor genes [24, 25].
Although the non-genome-incorporating adenoviral gene
delivery systems can be used for high levels and persistent
expressions of therapeutic genes, their therapeutic poten-
tials are limited by the immune reactions to viral proteins
[26–30]. Their applications in spinal discs near to sensitive
neural structure could induce toxicity and immunological
side-effects, which could result in neurological deficits
and serious pain [31–33, 44, 47, 48]. Therefore, the
adeno-associated viral gene delivery system, which does
not express any viral protein and is not linked with any
known disease in humans, has become an interesting
therapeutic gene delivery system. Several studies concern-
ing the potential applications of AAV for gene therrapeu-
tic approaches of degenerative discs have been published
[49–54]. AAV2 mediated in vitro co-transfection of bone
morphogenetic protein 7 (BMP-7) and transcription factor
SOX-9 has been shown to promote the expression of col-
lagen II in degenerative human NP cells [49]. Similarly
AAV2 mediated in vivo co-transfection of BMP-7 and
SOX-9 could enhance the expression of collagen II and
proteoglycan, and significantly improve the height of de-
generative rabbit discs [50]. Furthermore, AAV2 mediated
in vitro co-transfection of vascular endothelial growth fac-
tor165 (hVEGF165) and transforming growth factor-β1
(TGF-β1) has been presented to increase the synthesis of
collagen I in degenerative anulus fibrosis cells of rabbit
[51]. However in preimmunized rabbits, due to humoral
immune response against the AAV vector, decreased
transgene expressions have been described [52]. AAV2
based in vitro and in vivo testing of gene expression in
rabbit IVD has demonstrated the potential of AAV system
to improve safety without nonspecific gene expression or
expression in adjacent tissues [53]. Adenoviral mediated
delivery of anabolic cytokines into the lumbar epidural
space of rabbits has demonstrated significant clinical, bio-
chemical, and histologic morbidit by up to 80 % of the
rabbits. Conversely, AAV mediated delivery of any ana-
bolic cytokin resulted in no clinical, histologic, or bio-
chemical morbidity [54]. AAV can have high transduction
Table 3 Viability of NP cells transduced with scAAV2, scAAV3
and scAAV6
Day post-transduction day 8 day 16 day 24 day 32 day 48
Control Mean 149148 192663 258666 334200 589681
SD 1009 1027 3446 2628 3362
scAAV2 Mean 113127 146759 198713 252733 463623
SD 1668 1863 3214 3745 3952
scAAV3 Mean 123754 166629 233436 291172 529090
SD 1406 1541 1878 4370 4556
scAAV6 Mean 145643 189679 254178 330270 586593
SD 1411 1540 2977 4966 4967
1 x 105 NP cells were transduced scAAV2, scAAV3 and scAAV6 at a viral dose
of 5000 vg/c. On day 8, 16, 24, 32 and 48 of post-transduction MTT assays were
performed to measure the number of viable cells. Data represent the mean number
of viable cells with standard deviation (SD) of three independent experiments, each
performed in duplicate (p< 0.05)
Fig. 3 NP cell viabilities after transduction with scAAV2, scAAV3 and scAAV6. A viral dose of 5000 vg/c was used to transduce 1 x 105 NP cells with
scAAV2, scAAV3 and scAAV6. After transduction MTT assays were done on day 8, 16, 24, 32 and 48 of post-transduction to quantify the number of
viable cells. Data represent the mean number of viable cells with standard deviation (SD) of three independent experiments, each performed in
duplicat (p < 0.005). Error bars indicate SD values
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efficiency and permits prolonged expression of therapeutic
gene [34, 35]. The self-complementary AAV (scAAV) con-
taining a terminal resolution site mutation and a deletion
of D-sequence in the right ITR can prevent Rep mediated
nicking and permit efficient infection as well as improved
transgene expression [36, 55]. Despite great advantages of
using AAVs as vectors, there are some limitations due to
their small genome size (4.7 kbp), as large genes are not
convenient for cloning in AAV vectors. Moreover, the
cloning capacity of scAAVs is even less than the already
limited cloning capacity of standard AAVs. However, while
a standard AAV packages a single strand DNA and must
wait for the complementary strand to be synthesized,
scAAV packages two shorter strands that are complemen-
tary to each other. By avoiding complementary strand syn-
thesis, scAAV can more quickly express therapeutic target
genes. Nevertheless, standard AAV and scAAV vectors
have been widely used for the delivery of small therapeutic
genes (up to 3.0 kbp) and shRNA expression cassettes in
RNAi approaches. Options are currently being explored to
overrid this limiting capacity. For instance the ITRs of two
AAV genomes can anneal to form head to tail concata-
mers, which could almost double the coding capacity of
the vector.
In human several AAV serotypes with differences in
tissue tropism have been described [37]. AAV serotypes
regarding human IVD have not been studied. No re-
search has been performed to identify and characterize
human IVD specific AAV serotypes. Their transduction
efficiency and cell cytotoxicity have not yet been evalu-
ated in human IVD cells. Therefore, we attempted to
effectively target human NP cells using different scAAV
serotypes and evaluated their transduction efficiency, cell
cytotoxicity and effect on the expression of inflamma-
tory, catabolic and matrix proteins. The initial screening
of the scAAV serotypes showed that only the serotypes
scAAV2, scAAV3 and scAAV6 could transduce NP cells
and their highest transduction efficiencies were obtained
at the dose of 5000 vg/c by day 8 (Fig. 1). Consequently,
the three serotypes [5000 vg/c] were selected to be used
for quantitativ analysis of GFP positive cells by FACS.
Compared to scAAV2 and scAAV3, the setotype scAAV6
steadily showed the highest transduction efficiencies in
all days of GFP positive cell detection (Table 2 and
Fig. 2). However, for all serotypes the number of GFP
positive cells was gradually decreased from day 8 to 48:
from 98.6 % to 38 % for scAAV6, from 91.6 % to 31.2 %
for scAAV2 and from 89.6 % to 29.4 % for scAAV3.
These continuous reductions in number of GFP positive
cells could be due to the fact that NP cells continually
devide and as a result of which the AAV vector genome
got diluted over time in the growing cell population.
The dilution of the AAV vector genome was in line with
our expectation, as AAV episome could be lost during
cell division [34, 35, 56]. Nevertheless, the recorded
long-term transgen expressions are promissing for gene
therapeutic approaches of degenerative IVDs, which
usually need prolonged regeneration time (weeks to
monthes). To investigate the impact of the three scAAV
serotypes on NP cell viability, MTT assays were per-
formed. These lower viabilities of scAAV2 and scAAV3
treated NP cells (Table 3 and Fig. 3) might be caused by
the immune respons of NP cells to the high dose [5000
vg/c] of scAAV2 and scAAV3, which feature about 88 %
sequence homology [57]. Despite the fact that the trans-
duction of NP cells with lower dose of scAAV2 and
scAAV3 [3000 vg/c] improved the cell viabilities by 9 %
and 12 %, the maximum transduction efficiencies
remained below 60 % (data not shown).
Increased protein levels of inflammatory cytokines (IL-
1β, TNF-α) and catabolic factors (ADAMTS-4, ADAMTS-
5) are considerd to be solid indicators of inflammatory
catabolic changes in intervertebral discs [16–18, 58–60].
Increased catabolism in NP tissue, mediated by the inflam-
matory cytokines and the catabolic factors, reduces the
levels the extracellular matrix proteins (aggrecan and
Fig. 4 Proliferating NP cells on day 16 after transduction with scAAV6. A viral dose of 5000 vg/c was used to transduce 1 x 105 NP cells with scAAV6 at
50 % confluent and about 95 % viabilily. Images show bright field views of scAAV6 treated and untreated control NP cells on day 16 of post-transduction.
Morphological chages were not observed as shown as an example herein. Original magnification: x 20
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Fig. 5 scAAV6 treated NP cells and their expression levels of inflammatory, catabolic and matrix proteins. 1 x 105 NP cells from grade III samples
were monolayer transduced with scAAV6 [5000 vg/c] and 3D cultured for four weeks in collagen I scaffold. To determine expression levels of
inflammatory, catabolic and matrix proteins [pg/ml], ELISA assays were performed using 100 μg of total protein extracts from each sample. Box
plots with whiskers min. to max. show the expression levels of the inflammatory cytokines IL-1β and TNF-α (a, b), the catabolic factors ADAMTS-4
and ADAMTS-5 (c, d) and the IVD matrix proteins aggrecan and collagen II (e, f). Data were obtained from three independent experiments, each
performed in duplicate (p < 0.05)
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collagen II) [16–18]. Since scAAV6 displayed the highest
transduction efficency and no impact on NP cell viability,
it was chosen for the detection of inflammatory catabolic
responses. Using ELISA assays comparable protein expres-
sion levels were detected in untreated and scAAV6 treated
NP cells (Table 4 and Fig. 5), indicating no inflammatory
catabolic responses of NP cells to scAAV6.
Conclusions
This is the first study to identify, characterize and evalu-
ate AAV serotypes in degenerative human IVDs. Here
we identified scAAV2, scAAV3 and scAAV6, which
could efficiently transduce human NP cells. scAAV6
seems to be the most convenient for gene therapeutic
approaches of degenerative IVDs, as it showed the high-
est transduction efficiency without any effect on NP cell
viability, and did not show any impact on the expression
of inflammatory, catabolic and matrix proteins. This
study might help to design efficient, stable and less im-
munogenic gene therapeutic approaches to impede
degeneration of spinal discs.
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